iiinova — where your digital self keeps evolving

Paul Bollyky

@pbollyky.bsky.social

253 followers 160 following 13 posts

Stanford University Infectious Disease Doc studying bacteriophages, bacterial infections, and innate immunity.

Posts Replies Media

Paul Bollyky @pbollyky.bsky.social · 09/07/2025

Check it out - phages seem to cross the placenta from mom to fetus! Check it out here: insight.jci.org/articles/vie... Congrats to Jen Sequioia, Naomi Haddock and our terrific collaborators in the Winn Lab

193 0

Paul Bollyky @pbollyky.bsky.social · 23/01/2025

Very excited to see this preprint from @JasonAndrewsMD on a method using phages to detect environmental pathogens - this is a terrific idea www.medrxiv.org/content/10.1...

030 0

Paul Bollyky @pbollyky.bsky.social · 06/01/2025

Enjoyed reading these encouraging results from a new phage therapy trial in diabetic foot ulcers. www.cell.com/med/abstract...

cell.com

Randomized double-blind study on safety and tolerability of TP-102 phage cocktail in patients with infected and non-infected diabetic foot ulcers

The bacteriophage formulation TP-102 was tested in a phase I/IIa clinical trial and was well tolerated. No significant adverse events were observed, suggesting its therapeutic potential for bacterial infections in diabetic foot ulcers.

060 0

Paul Bollyky @pbollyky.bsky.social · 11/12/2024

We find JukA (formerly YaaW, WP_003137196.1) in 10 of our 80 CPA. With OMK01, The 10 Juk+ strains are resistant but so are 66 Juk- strains. The 4 susceptible strains are indeed Juk-. The association with Juk was non-significant.

100 0

Paul Bollyky @pbollyky.bsky.social · 07/12/2024

I'm thrilled to welcome our new class of Infectious Disease fellows to Stanford! We are so excited have such a talented group of physicians coming to join us next year.

3130 0

Paul Bollyky @pbollyky.bsky.social · 06/12/2024

Thanks for these great questions Chase and for your interest in our work!

000 0

Paul Bollyky @pbollyky.bsky.social · 06/12/2024

In a recent pre-print, we used transposon mutagenic to identify the receptors for OMK01 and find that it indeed used flagella www.biorxiv.org/content/10.1...

biorxiv.org

Bacterial Receptors but Not Anti-Phage Defence Mechanisms Determine Host Range for a Pair of Pseudomonas aeruginosa Lytic Phages

Lytic bacteriophages (phage), viral predators of bacteria, offer a promising solution for treating bacterial infections. However, the narrow host range of phages limits the broad utility of individual...

100 0

Paul Bollyky @pbollyky.bsky.social · 06/12/2024

With closely related phages having distinct receptor usage patterns, we address this in figure 2 - we find that this is the case for several phages, suggesting that phages may switch receptors with some frequency.

biorxiv.org

Bacterial Receptors but Not Anti-Phage Defence Mechanisms Determine Host Range for a Pair of Pseudomonas aeruginosa Lytic Phages

110 0

Paul Bollyky @pbollyky.bsky.social · 06/12/2024

I would wonder what MOI was used in other studies with phikz and PA14. We used 100.

200 0

Paul Bollyky @pbollyky.bsky.social · 04/12/2024

Thank you!!

000 0

Paul Bollyky @pbollyky.bsky.social · 02/12/2024

Many thanks to our outstanding collaborators including Liz Burgener, Carlos Milla, and Niaz Banaei

030 0

Paul Bollyky @pbollyky.bsky.social · 02/12/2024

In this work, we describe a streamlined protocol for identifying cross-resistant phages and antibiotics, which we call complementarity grouping. Cocktails targeting 3 or more complementarity groups were effective vs >80% of P. aeruginosa isolates. Add a synergistic antibiotic and its >96%

160 0

Paul Bollyky @pbollyky.bsky.social · 02/12/2024

Excited to share our work on broadly effective phage-antibiotic cocktails. We report 4 cocktails that each work against 96% of 153 antibiotic resistant Pseudomonas isolates. Check it out here: www.nature.com/articles/s41... Congrats to Kevin Kim @KevinMinyo6651

nature.com

A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections - Nature Communications

The application of phage therapy for multidrug-resistant infections is mainly limited to personalized therapy due to the narrow host range of individual phages. Here, Kim et al. identify groups of pha...

47227 0